Hyperparathyroidism Clinical Trial
Official title:
Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery
We hypothesized that pre-treatment with methylene blue could potentiate the effects of general anaesthetic agents in patients undergoing parathyroidectomy
Sample and study design The local ethics committee granted approval for this study and
informed written consent will be obtained from all participants. We will study ASA grade I
or II patients, aged between 45 and 73 years who were free from cardiovascular and pulmonary
diseases. Patients with psychiatric disorders or drug abuse as well as those weighing 20%
more or less than their ideal body weight will all be excluded.
The interventional group will consist of 11 patients scheduled for elective
parathyroidectomy who will receive MB infusion (5mg.kg-1 in 250 ml 5% glucose-saline)
approximately 60 min before anaesthesia induction. A further 11 patients scheduled for
unilateral thyroid lobectomy without MB pre-treatment will be recruited as controls. They
will present with normal thyroid tests and will carefully be selected in an attempt to match
the intervention group on the basis of age, weight and sex. Both types of surgical
procedures will be performed by the same surgical team.
Anaesthesia and surgery All patients will be premedicated with oral midazolam 7.5 mg and
they will receive a loading dose of lactate-ringer solution (5 ml.kg-1) intravenously after
arrival in the operating theatre. The standard anaesthetic monitoring will comprise
non-invasive blood pressure, ECG, pulsed oxygen saturation and end-tidal carbon dioxide.
Processed EEG parameters will be acquired with a BIS monitor, using surface electrodes, with
impedance maintained at less than 5kΩ to ensure adequate signal quality. Raw EEG data from
two channels (F7-CZ and F8-CZ) will be processed by company proprietary software and the BIS
values (calculated for each 4-sec epoch) will be continuously displayed along with the trend
line.
Propofol will be infused using a commercially available TCI system loaded with Schneider's
3-compartment pharmacokinetic model wherein the individual patient's age, height and weight
will be programmed. The target effect-site concentration of propofol will be computed to
yield a time to peak effect of 1.6 min, which has been confirmed clinically.
During anaesthesia induction, the patients will breath an air-oxygen mixture through a face
mask. The target effect-site concentration of propofol will first be set at 0.5 ng.ml-1 and
it will be increased by 0.2 ng.ml-1 every 2 min until the clinical endpoint will be achieved
(loss of consciousness and unresponsiveness). Then, ventilation will be assisted manually
and the trachea will be intubated after the intravenous administration of fentanyl (100 mcg)
and rocuronium (0.7 mg.kg-1).
During anaesthesia maintenance, the effect-site concentration of propofol will be targeted
to achieve BIS values between 30 and 60. Additional fentanyl, rocuronium or vasopressor
agents (ephedrine) will be given at the discretion of the attending anaesthetist.
Measurements When each patient will be comfortable on the operating table, baseline
measurements of BIS, mean arterial pressure (MAP), heart rate (HR) and pulsed oxygen
saturation (SpO2) will be taken.
During propofol induction, BIS values, MAP, HR and SpO2 will be recorded every 1-min and the
Observer's Assessment of Alertness/Sedation (OAAS) rating scale will be recorded after each
equilibration period (score 5=awake and responds readily to name spoken in normal tone; 4=
lethargic response to name in normal tone; 3=response only after name is called loudly
and/or repeatedly; 2= response only after name is called loudly and after mild shaking; 1=
dose not respond when name is called and after mild shaking).
During surgery and anaesthesia maintenance, BIS values and the effect-site concentration of
propofol will be recorded each 5-min.
Other recorded data will include the doses of propofol required for anaesthesia induction
and maintenance, the total amount of vasopressor and the time until anaesthesia emergence
and readiness for tracheal extubation.
Statistics Assuming that MB pre-treatment would reduce the requirement of propofol by 25%,
power analysis with alpha = 0.05, beta = 0.8, shows that we would need to study at least 10
patients in each group. The computer program SAS 8.0 for Windows will be used for all data
analyses. Parametric data will be analysed by two-way ANOVA. Unpaired Student t-tests,
Chi-squared tests and Fisher's exact probability tests will be used as appropriate for
comparison between groups. All values are expressed as mean (M), standard deviation (SD) and
statistical significance will be accepted at p < 0.05.
;
Observational Model: Case Control, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00377312 -
7 Day Continuous Parathyroid Hormone IV Infusion
|
Phase 0 | |
Completed |
NCT04040946 -
Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention
|
Phase 3 | |
Recruiting |
NCT03053999 -
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
|
||
Withdrawn |
NCT02711059 -
Insulin Resistance in Primary Hyperparathyroidism
|
N/A | |
Completed |
NCT01691781 -
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
|
N/A | |
Completed |
NCT00538720 -
Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)
|
Phase 1 | |
Completed |
NCT00887666 -
Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure
|
N/A | |
Terminated |
NCT03044600 -
Gene Expression in Hyperparathyroidism
|
||
Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
Completed |
NCT01872429 -
Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients
|
N/A | |
Completed |
NCT00800358 -
Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism
|
N/A | |
Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
Completed |
NCT03968510 -
Swalqol in Primary Hyperparathyroidism
|
||
Completed |
NCT00501215 -
Effect of Parathyroidectomy on Sleep
|
N/A | |
Completed |
NCT02591160 -
Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism
|
N/A | |
Recruiting |
NCT05299632 -
F-18 PSMA for Localization of Parathyroid Adenoma
|
||
Recruiting |
NCT02986607 -
Corticosteroid Rhythms in Hypoparathyroid Patients
|
Early Phase 1 | |
Completed |
NCT02432599 -
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
|
Phase 2 | |
Completed |
NCT02524041 -
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism
|
N/A |